Cargando…

Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain

Current guidelines recommend temozolomide as the first-line chemotherapy for aggressive pituitary neuroendocrine tumours. However, no clinical trials have been conducted to date and clinical experience is quite limited. We retrospectively analyzed 28 patients (9 women and 19 men), aged 46.6 + 16.9,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lamas, Cristina, Cámara, Rosa, Fajardo, Carmen, Remon-Ruiz, Pablo, Biagetti, Betina, Guerrero-Pérez, Fernando, Araujo-Castro, Marta, Mora, Mireia, Hanzu, Felicia, Iglesias, Pedro, García-Centeno, Rogelio, Soto, Alfonso
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500829/ https://www.ncbi.nlm.nih.gov/pubmed/37720528 http://dx.doi.org/10.3389/fendo.2023.1204206

Ejemplares similares

Preference of acromegaly patients for treatment attributes in Spain
por: Fajardo, Carmen, et al.
Publicado: (2023)

Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report
por: Mirallas, Oriol, et al.
Publicado: (2021)

Temozolomide in aggressive pituitary adenomas and carcinomas
por: Ortiz, Leon D., et al.
Publicado: (2012)

Pituitary Apoplexy: Risk Factors and Underlying Molecular Mechanisms
por: Biagetti, Betina, et al.
Publicado: (2022)

Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features
por: Vázquez-Borrego, Mari C., et al.
Publicado: (2019)

SUN-272 Significant Response to Temozolomide in Two Aggressively Growing Pituitary Adenomas
por: Kreitschmann-Andermahr, Ilonka, et al.
Publicado: (2020)

Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas
por: Das, Liza, et al.
Publicado: (2021)

How Valuable Is the RT-qPCR of Pituitary-Specific Transcription Factors for Identifying Pituitary Neuroendocrine Tumor Subtypes According to the New WHO 2017 Criteria?
por: Torregrosa-Quesada, María Eugenia, et al.
Publicado: (2019)

The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up
por: Ferrés, Abel, et al.
Publicado: (2022)

Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas with Adjuvant Temozolomide Chemotherapy: A Review
por: Moisi, Marc, et al.
Publicado: (2016)

MON-406 Two Cases of Aggressive Corticotroph Pituitary Tumors Treated with Capecitabine and Temozolomide
por: Tateno, Tae, et al.
Publicado: (2019)

Clinical Efficacy of Temozolomide and Its Predictors in Aggressive Pituitary Tumors and Pituitary Carcinomas: A Systematic Review and Meta-Analysis
por: Luo, Mei, et al.
Publicado: (2021)

Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina
por: Bruno, Oscar D., et al.
Publicado: (2015)

Temozolomide and Capecitabine Treatment for an Aggressive Somatotroph Pituitary Tumor: A Case Report and Literature Review
por: Ishida, Atsushi, et al.
Publicado: (2022)

Increased E2F1 mRNA and miR-17-5p Expression Is Correlated to Invasiveness and Proliferation of Pituitary Neuroendocrine Tumours
por: García-Martínez, Araceli, et al.
Publicado: (2020)

A Rapid Biochemical and Radiological Response to the Concomitant Therapy with Temozolomide and Radiotherapy in an Aggressive ACTH Pituitary Adenoma
por: Misir Krpan, Ana, et al.
Publicado: (2017)

Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art
por: Feola, Tiziana, et al.
Publicado: (2022)

Long-term remission in an aggressive Crooke cell adenoma of the pituitary, 18 months after discontinuation of treatment with temozolomide
por: Asimakopoulou, Athina, et al.
Publicado: (2014)

Molecular characterization of epithelial-mesenchymal transition and medical treatment related-genes in non-functioning pituitary neuroendocrine tumors
por: Gil, Joan, et al.
Publicado: (2023)

Is it time to consider the expression of specific-pituitary hormone genes when typifying pituitary tumours?
por: García-Martínez, Araceli, et al.
Publicado: (2018)

Temozolomide therapy: Focus on patients with pituitary carcinoma
por: Curtò, Lorenzo
Publicado: (2016)

MON-407 Tumor Control after Radiotherapy and Temozolomide in a Cushing's Disease Patient with Giant Aggressive Pituitary Tumor
por: Valente do Couto, Hugo, et al.
Publicado: (2019)

Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary
por: Chauhan, Aman, et al.
Publicado: (2018)

Contribution of molecular analysis to the typification of the non-functioning pituitary adenomas
por: Sanchez-Tejada, Laura, et al.
Publicado: (2017)

Post first-line dacarbazine or temozolomide in neuroendocrine carcinoma
por: Couronne, Thomas, et al.
Publicado: (2020)

Pituitary macroadenomas in childhood and adolescence: a clinical analysis of 7 patients
por: Aguilar-Riera, Cristina, et al.
Publicado: (2023)

Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
por: Marques-Pamies, Montserrat, et al.
Publicado: (2023)

Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes
por: Das, Liza, et al.
Publicado: (2021)

Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRAXIS program Delphi survey
por: de Pablos-Velasco, Pedro, et al.
Publicado: (2019)

A Case of Nonfunctioning Pituitary Carcinoma That Responded to Temozolomide Treatment
por: Morokuma, Haruko, et al.
Publicado: (2012)

Surgical treatment of aggressive pituitary adenomas and pituitary carcinomas
por: Buchfelder, Michael, et al.
Publicado: (2020)

Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas
por: Olsen, Ingrid H., et al.
Publicado: (2012)

Neoadjuvant Chemotherapy with Capecitabine and Temozolomide for Unresectable Pancreatic Neuroendocrine Tumor
por: Devata, Sumana, et al.
Publicado: (2012)

Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs)
por: Thomas, Katharine, et al.
Publicado: (2020)

Treatment of ampullary neuroendocrine tumor by Capecitabine (Xeloda®) and Temozolomide (Temodal®)
por: Noorali, Sima, et al.
Publicado: (2021)

Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors
por: Al-Toubah, Taymeyah, et al.
Publicado: (2022)

Cardiovascular Risk Associated With Gender Affirming Hormone Therapy in Transgender Population
por: Aranda, Gloria, et al.
Publicado: (2021)

Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain
por: Biagetti, Betina, et al.
Publicado: (2022)

Pituitary Apoplexy in Patients with Pituitary Neuroendocrine Tumors (PitNET)
por: Gheorghe, Ana-Maria, et al.
Publicado: (2023)

Aggressive prolactinomas responsive to temozolomide treatment: Report of two cases
por: Davoudi, Zahra, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lo8ddd39kfbocjjdl38e2rfbql